Chemicals

[Tyr8]-Atrial Natriuretic Peptide (5-27), rat; [Tyr8]-Atriopeptin II, rat

<p>[Tyr⁸]-Atrial Natriuretic Peptide (5-27), rat; [Tyr⁸]-Atriopeptin II, rat is a synthetic, tyrosine-substituted analog of rat atriopeptin II designed primarily as a precursor for radioiodination in receptor binding and autoradiography studies. This high-purity research peptide retains the core disulfide-bridged structure of the native natriuretic peptide, enabling specific interaction with natriuretic peptide rece…

SupplierGlobal Technology Co., Ltd.www.hqtechtirz.com
Source categories

About this product

Product information from the supplier.



TECHNICAL SPECIFICATIONS


Item
Specification
Product Name
[Tyr8]-Atrial Natriuretic Peptide (5-27), rat; [Tyr8]-Atriopeptin II, rat
CAS NO.
/
Appearance
White to off-white lyophilized powder
Molecular Formula
C98H156N34O33S2
Molecular Weight
 2402.7g/mol 
Purity (RP-HPLC)
≥ 95.0%
Solubility

Soluble in water, phosphate-buffered saline (PBS), or dilute acetic acid (e.g., 0.1%). It is recommended to first dissolve in a small volume of 0.1% acetic acid or sterile water to prepare a 0.1–1.0 mg/mL stock solution, then dilute with assay buffer.

Endotoxin< 1.0 EU/mg
Biological Activity
This peptide is a modified analog of rat atriopeptin II / ANP(5-27), where the substitution with tyrosine at position 8 may be designed for iodination (e.g., with ¹²⁵I) to create a radioligand for receptor binding studies. It retains the ability to bind to natriuretic peptide receptors (primarily NPR-A) and stimulate cGMP production, although its affinity and potency may differ from the native peptide. Biological activity should be confirmed by receptor binding assays or cGMP accumulation assays.
Storage Conditions
Lyophilized powder: Store desiccated at –20°C or below, protected from light, for long-term stability. Reconstituted solution: Aliquot and store at ≤ –20°C; avoid repeated freeze-thaw cycles.
Stock Location
Stock in USA
MOQ
1g


1.MECHANISM OF ACTION

The peptide functions as a ligand for natriuretic peptide receptors, primarily NPR-A, by binding to the extracellular domain of these guanylyl cyclase-coupled receptors. This engagement activates intracellular guanylyl cyclase, leading to increased cyclic GMP (cGMP) production. Elevated cGMP levels activate cGMP-dependent protein kinases, resulting in vasodilation, enhanced renal sodium and water excretion, and inhibition of the renin–angiotensin–aldosterone system. The [Tyr⁸] modification does not fundamentally alter this signaling cascade but provides a site for iodination, allowing the generation of radiolabeled tracers that retain receptor binding affinity for quantitative autoradiography and competition binding assays.


2.PRODUCT INDICATIONS

This [Tyr⁸]-modified rat ANP analog is indicated exclusively for research use in preclinical studies of natriuretic peptide receptor biology and cardiovascular physiology. It is employed as a precursor for radioiodination to produce [¹²⁵I]-Tyr⁸-ANP tracers for receptor binding assays, saturation and competition studies, and autoradiographic mapping of NPR distribution in tissues. The unlabeled peptide also serves as a cold competitor in displacement experiments and can be used in functional assays to assess cGMP accumulation and vascular relaxation in cell-based and isolated tissue preparations. It is not intended for diagnostic, therapeutic, or clinical applications in humans or animals.


3.CLINICAL EFFICACY OF PRODUCT

As a research reagent and radioligand precursor, [Tyr⁸]-Atrial Natriuretic Peptide (5-27), rat; [Tyr⁸]-Atriopeptin II, rat has no established clinical efficacy for therapeutic use in human patients. The product has not undergone clinical development, regulatory approval, or safety evaluation for any medical indication. While it contributes to the understanding of natriuretic peptide receptor dynamics and potential therapeutic targets for conditions like hypertension and heart failure, it remains an investigational tool for basic and translational research. Its utility is confined to laboratory applications, with no proven clinical benefits or safety profile in humans.


4.DELIVERY & SHIPPING

We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods 
Main Method: International Air Freight

We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.